253 related articles for article (PubMed ID: 34003992)
21. Anatomical and refractive outcomes in patients with treated retinopathy of prematurity.
Lolas M; Tuma A; Zanolli M; Agurto R; Stevenson R; Ossandón D
Arch Soc Esp Oftalmol; 2017 Oct; 92(10):472-476. PubMed ID: 28624314
[TBL] [Abstract][Full Text] [Related]
22. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
[TBL] [Abstract][Full Text] [Related]
23. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study.
Fan YY; Huang YS; Huang CY; Hsu JF; Shih CP; Hwang YS; Yao TC; Lai CC; Wu WC
Ophthalmology; 2019 Nov; 126(11):1567-1577. PubMed ID: 30954553
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
Bayramoglu SE; Sayin N
Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.
Gunay M; Celik G; Gunay BO; Aktas A; Karatekin G; Ovali F
Arq Bras Oftalmol; 2015; 78(5):300-4. PubMed ID: 26466229
[TBL] [Abstract][Full Text] [Related]
27. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.
Mueller B; Salchow DJ; Waffenschmidt E; Joussen AM; Schmalisch G; Czernik C; Bührer C; Schunk KU; Girschick HJ; Winterhalter S
Br J Ophthalmol; 2017 Mar; 101(3):365-370. PubMed ID: 27301450
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
29. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.
Mori Y; Arima M; Ueda E; Fujiwara K; Seki E; Nakama T; Tsukamoto S; Akiyama M; Sonoda KH
Eye (Lond); 2021 Oct; 35(10):2820-2825. PubMed ID: 33257802
[TBL] [Abstract][Full Text] [Related]
31. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
32. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
[TBL] [Abstract][Full Text] [Related]
33. Refractive outcome of premature infants with or without retinopathy of prematurity at 2 years of age: a prospective controlled cohort study.
Hsieh CJ; Liu JW; Huang JS; Lin KC
Kaohsiung J Med Sci; 2012 Apr; 28(4):204-11. PubMed ID: 22453068
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
[TBL] [Abstract][Full Text] [Related]
35. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.
Anand N; Blair MP; Greenwald MJ; Rodriguez SH
J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978
[TBL] [Abstract][Full Text] [Related]
36. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
[TBL] [Abstract][Full Text] [Related]
37. Electroretinographic Responses in Retinopathy of Prematurity Treated Using Intravitreal Bevacizumab or Laser.
Curran AK; Stukin J; Ambrosio L; Mantagos IS; Wu C; Vanderveen DK; Hansen RM; Akula JD; Fulton AB
Am J Ophthalmol; 2023 Aug; 252():275-285. PubMed ID: 37146743
[TBL] [Abstract][Full Text] [Related]
38. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
[TBL] [Abstract][Full Text] [Related]
39. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
[TBL] [Abstract][Full Text] [Related]
40. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
Sindal MD; Nagesha CK; Yadav D; Fazal R
Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
